University of Wyoming, CaaMTech to Study Potential of Psychedelic Compounds to Treat Addiction

The University of Wyoming School of Pharmacy announced that it has formed a collaboration with CaaMTech, a Washington state-based developer of psychedelic drugs, to evaluate the company’s proprietary compounds as treatments for addiction.

Ana Clara Bobadilla, an assistant professor in the school, is leading the research project.

CaaMTech creates and optimizes psychedelic compounds and formulations, creating novel tryptamines that “are specifically engineered to optimize desired effects while minimizing unwanted side-effects,” according to its website.

Researchers will evaluate CaaMTech’s library of compounds using established preclinical addiction models. The project will also aim to demonstrate predicted therapeutic properties to treat drug craving. Poly-reward models of self-administration and relapse will be used.

“For over 50 years, psychedelics have been classified as drugs with a high potential for abuse and no therapeutic value,” CaaMTech CEO Andrew Chadeayne said in a University of Wyoming news release. “With this research collaboration, we aim to show that CaaMTech’s compounds have minimal risk of addiction and also tremendous potential for treating it.”